Treatment of Children and Adolescents with Epilepsy with Atomoxetine
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective The objective of this study was to assess the effectiveness and safety of atomoxetine in Korean children and adolescents with epilepsy. Methods We retrospectively reviewed the electronic medical records of 105 children and adolescents with epilepsy treated with atomoxetine. Effectiveness was measured with the Clinical Global Impressions-Severity (CGI-S) and/or Clinical Global Impressions-Improvement (CGI-I) scales at baseline, and after 4 and 12 weeks. We defined response to atomoxetine as a CGI-I score less than three at week 12. Safety was evaluated at each visit, based on clinical assessment by a child and adolescent psychiatrist and reports from participants or their caregivers. Results In total participants (n=105), 33 (31.4%) showed a response to treatment: a significant decrease in CGI-S scale score was observed over 12 weeks of atomoxetine treatment. The most common adverse event (AE) was decreased appetite (n=16, 15.2%), and life-threatening AEs were not observed. Seizure aggravation due to atomoxetine was observed in 7.6% (n=8) of total participants, and one of them discontinued atomoxetine. Conclusion Our results provide preliminary evidence of the effectiveness and safety of atomoxetine in children and adolescents with epilepsy.
Abstract
Objective The objective of this study was to assess the effectiveness and safety of atomoxetine in Korean children and adolescents with epilepsy. Methods We retrospectively reviewed the electronic medical records of 105 children and adolescents with epilepsy treated with atomoxetine. Effectiveness was measured with the Clinical Global Impressions-Severity (CGI-S) and/or Clinical Global Impressions-Improvement (CGI-I) scales at baseline, and after 4 and 12 weeks. We defined response to atomoxetine as a CGI-I score less than three at week 12. Safety was evaluated at each visit, based on clinical assessment by a child and adolescent psychiatrist and reports from participants or their caregivers. Results In total participants (n=105), 33 (31.4%) showed a response to treatment: a significant decrease in CGI-S scale score was observed over 12 weeks of atomoxetine treatment. The most common adverse event (AE) was decreased appetite (n=16, 15.2%), and life-threatening AEs were not observed. Seizure aggravation due to atomoxetine was observed in 7.6% (n=8) of total participants, and one of them discontinued atomoxetine. Conclusion Our results provide preliminary evidence of the effectiveness and safety of atomoxetine in children and adolescents with epilepsy.
참고문헌 (23)
- American Psychiatric Association, "Diagnostic and Statistical Manual for Mental Disorder 5(DSM-5)", American Psychiatric Association, ~ (2013)
- Barkely RA, "Attention Deficit Hyperactivity Disorder : A Handbook for Diagnosis and Treatment" (2015), The Guilford Press
- Volk HE, "A systematic evaluation of ADHD and comorbid psychopathology in a population-based twin sample", J Am Acad Child Adolesc Psychiatry, 44, pp.768~775 (2005)
- Dunn DW, "ADHD and epilepsy in childhood", Dev Med Child Neurol, 45, pp.50~54 (2003)
- Dunn DW, "Differential diagnosis and treatment of psychiatric disorders in children and adolescents with epilepsy", Epilepsy Behav, 5(Suppl 3), pp.S10~S17 (2004)
- Hermann B, "The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy", Brain, 130, pp.3135~3148 (2007)
- Briars L, "A review of pharmacological management of attentiondeficit", hyperactivity disorder, 2016, pp.21, 192~206
- Torres AR, "Attention-deficit", hyperactivity disorder in pediatric patients with epilepsy : review of pharmacological treatment, 2008, pp.12, 217~233
- Park JH, "Relationship between aggravation of seizures and methylphenidate treatment in subjects with attention-deficit", hyperactivity disorder and epilepsy, 2018, pp.28, 537~546
- Salpekar JA, "Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy", Epilepsy Behav, 37, pp.310~315 (2014)
- Stevens JR, "Using stimulants for attention-deficit", hyperactivity disorder : clinical approaches and challenges, 2013, pp.15, 12f01472~
- Reilly CJ, "Attention deficit hyperactivity disorder(ADHD)in childhood epilepsy", Res Dev Disabil, 32, pp.883~893 (2011)
- Torres A, "Tolerability of atomoxetine for treatment of pediatric attention-deficit", hyperactivity disorder in the context of epilepsy, 2011, pp.20, 95~102
- Fisher RS, "Operational classification of seizure types by the International League Against Epilepsy : position paper of the ILAE commission for classification and terminology", Epilepsia, 58, pp.522~530 (2017)
- Fisher RS, "Instruction manual for the ILAE 2017 operational classification of seizure types", Epilepsia, 58, pp.531~542 (2017)
- Guy W, "Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology", US Department of Health, Education, and Welfare Publication, National Institute of Mental Health, ~ (1976)
- Weiss M, "Characteristics of ADHD symptom response", remission in a clinical trial of methylphenidate extended release, 2019, pp.8, pii: E461~
- Newcorn JH, "Clinical responses to atomoxetine in attention-deficit", hyperactivity disorder : the Integrated Data Exploratory Analysis(IDEA)study, 2009, pp.48, 511~518
- Dittmann RW, "Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder", CNS Drugs, 28, pp.1059~1069 (2014)
- 박기정, "Clinical and Neuropsychological Factors Associated with Treatment Response and Adverse Events of Atomoxetine in Children with Attention-Deficit", Hyperactivity Disorder, 2019, pp.30(2), 74~82[DOI]
- Wernicke JF, "Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine", Dev Med Child Neurol, 49, pp.498~502 (2007)
- Hernandez J, "Efficacy of atomoxetine treatment in children with ADHD and epilepsy", Neuropediatrics, 37, pp.THP12~ (2006)
- Ravi M, "Epilepsy, attention-deficit", hyperactivity disorder and methylphenidate : critical examination of guiding evidence, 2016, pp.25, 50~58